Table 1 General characteristics of dialysis patients with NT or MUCH

From: Masked uncontrolled hypertension in patients on maintenance hemodialysis

 

Definition-1

Definition-2

Definition-3

Variables

NT

MUCH

NT

MUCH

NT

MUCH

Age, years

55.1±12.4

53.7±12.1

55.8±12.2

53.5±12.3

55.6±12.2

54.1±12.3

Male

36 (43.9%)

32 (50.8)

30 (46.9%)

38 (46.9%)

19 (51.4%)

49 (45.4%)

BMI, kg m−2

22.7±3.7

21.7±3.1

23.0±3.6

21.8±3.4a

23.6±4.0

21.9±3.2a

Current smoker

15 (18.3%)

14 (22.2%)

13 (20.3%)

16 (19.8%)

8 (21.6%)

21 (19.4%)

Dialysis vintage, months

79.3±56.1

73.0±61.3

79.9±54.7

73.8±61.2

79.8±53.1

75.4±60.1

IDWG, kg

2.5±0.8

2.2±0.8a

2.6±0.8

2.2±0.8a

2.6±0.9

2.3±0.8a

Diabetes

10 (12.2%)

8 (12.7%)

7 (10.9%)

11 (13.6%)

4 (10.8%)

14 (13.0%)

History of CVD

3 (3.7%)

5 (7.9%)

3 (4.7%)

5 (6.2%)

1 (2.7%)

7 (6.5%)

Use of antihypertensives

31 (37.8%)

50 (79.4%)a

20 (31.3%)

61 (75.3%)a

9 (24.3%)

72 (66.7%)a

CCB

18 (22%)

41 (65.1%)

10 (15.6%)

49 (60.5%)

4 (10.8%)

55 (50.9%)

ACEI/ARB

7 (8.5%)

18 (28.6%)

6 (9.4%)

19 (23.5%)

3 (8.1%)

22 (20.4%)

ß-blocker

23 (28.0%)

29 (46.0%)

14 (21.9%)

38 (46.9%)

5 (13.5%)

47 (43.5%)

Others

7 (8.5%)

15 (23.8%)

4 (6.3%)

18 (22.2%)

2 (5.4%)

20 (18.5%)

Use of EPOb

66 (80.5%)

54 (85.7%)

51 (79.7%)

69 (85.2%)

27 (73.0%)

93 (86.1%)

Use of statins

3 (3.7%)

4 (6.3%)

2 (3.1%)

5 (6.2%)

1 (2.7%)

6 (5.6%)

Hemoglobin, g l−1

112.7±14.3

107.8±15.0a

114.0±14.7

107.9±14.4a

115.3±16.3

109.0±13.9a

Albumin, g l−1

39.6±4.5

39.1±4.4

39.6±4.7

39.2±4.3

39.6±5.3

39.3±4.2

Total cholesterol, mmol l−1

4.04±0.94

4.07±0.85

4.03±0.92

4.07±0.89

3.93±0.94

4.09±0.88

Triglyceride, mmol l−1

2.25±1.34

1.90±1.13

2.20±1.16

2.01±1.33

2.21±1.31

2.06±1.25

HDL cholesterol, mmol l−1

0.97±0.26

1.04±0.27

0.95±0.24

1.03±0.29

0.92±0.25

1.02±0.27a

LDL cholesterol, mmol l−1

2.11±0.60

2.09±0.55

2.14±0.59

2.07±0.56

2.08±0.58

2.11±0.57

Phosphorus, mmol l−1

1.83±0.50

1.77±0.51

1.84±0.49

1.77±0.52

1.77±0.51

1.81±0.50

Calcium, mmol l−1

2.27±0.29

2.30±0.28

2.25±0.31

2.30±0.27

2.22±0.33

2.30±0.27

Parathyroid hormone, pg ml−1

231.6 (78.8–461.0)

232.6 (118.5–492.2)

229.4 (67.6–435.7)

235.6 (115.6–514.0)

186.2 (29.1–352.4)

237.1a (118.7–516.1)

CRP, μg ml−1

8.26 (2.94–19.62)

6.11 (3.12–17.33)

10.32 (2.71–20.00)

5.62 (3.27–15.22)

12.07 (2.92–23.5)

5.61 (3.15–14.63)

  1. Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CRP, C-reactive protein; CVD, cardiovascular disease; HDL, high-density lipoprotein; IDWG, interdialytic weight gain; LDL, low-density lipoprotein; MUCH, masked uncontrolled hypertension; NT, normotension.
  2. aindicates statistically significant compared with NT.
  3. bEPO was administered intravenously.